For citations:
RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY. Rational Pharmacotherapy in Cardiology. 2017;13(2):284. (In Russ.)
RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY. Rational Pharmacotherapy in Cardiology. 2017;13(2):284. (In Russ.)